Anlotinib is a small-molecule multi-targeted tyrosine kinase inhibitor classified as an anti-tumor agent. It is primarily indicated for the treatment of advanced malignancies including non-small cell lung cancer, soft tissue sarcoma, and medullary thyroid carcinoma.
It exerts its therapeutic effects by inhibiting tumor angiogenesis and tumor cell proliferation. As a prescription-only medication, it must be used under the guidance of a qualified physician.
